Aug 10, 2026
Tenax Therapeutics (TENX) Shares Collapse 84% on Failed Phase 3 Trial Results
Tenax Therapeutics (TENX) shares plummeted 84% after Phase 3 LEVEL trial failed primary and secondary endpoints for TNX-103 in PH-HFpEF treatment.
The post Tenax Therapeutics (TENX) Shares Collapse 84% on Failed Phase 3 Trial Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 55 minutes ago
ARK Invest Exits AMD (AMD) Position, Reallocates to Broadcom and Cerebras
- 1 hour ago
PayPal (PYPL) Plunges 13% After Stripe-Advent Consortium Abandons Takeover Bid
- 1 hour ago
Rubrik (RBRK) Stock Drops 8% Despite Strong Q2 Earnings Beat and Raised Guidance
- 1 hour ago
Autodesk (ADSK) Stock Slides 4% After Fiscal 2027 Earnings Outlook Disappoints
- 1 hour ago
Broadcom (AVGO) Stock: Should You Buy Ahead of Wednesday’s Earnings Report?